3/4/2014 7:30:12 AM
Britain's healthcare costs watchdog has asked U.S. biotech group Alexion Pharmaceuticals to explain the high price for its Soliris drug before deciding whether the treatment should be paid for by the state health service. Funding Soliris for the around 200 patients in England it could benefit would cost an estimated 58 million pounds ($97 million) in the first year, rising to 80 million pounds a year in five years time, the National Institute for Health and Care Excellence (NICE) said. Soliris is designed to treat two extremely rare chronic genetic conditions that can damage vital organs including the kidneys, heart and brain and has a U.S. list price of about $440,000 per patient a year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by